An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

• ClinicalTrials.gov Identifier: NCT02737475
• Recruitment Status: Completed
• First Posted: April 14, 2016
• Results First Posted: January 25, 2022
• Last Update Posted: January 25, 2022
• Sponsor: Bristol-Myers Squibb
• Information provided by (Responsible Party): Bristol-Myers Squibb

Tracking Information

• First Submitted Date: April 8, 2016
• First Posted Date: April 14, 2016
• Results First Submitted Date: November 2, 2021
• Results First Posted Date: January 25, 2022
• Last Update Posted Date: January 25, 2022
• Actual Study Start Date: June 17, 2016
• Actual Primary Completion Date: November 2, 2020 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: December 25, 2021)

• The Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) [ Time Frame: From first dose to 28 days after first dose ]
  The number of participants experiencing dose-limiting toxicities (DLTs) to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. DLTs are defined based on the incidence, severity, and duration of adverse events (AEs) for which no clear alternative cause is identified. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment.
• The Number of Participants Experiencing Adverse Events (AEs) [ Time Frame: From first dose to 100 days after last dose (up to approximately 2.5 years) ]
  The number of participants experiencing adverse events (AEs) to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment.
• The Number of Participants Experiencing Serious Adverse Events (SAEs) [ Time Frame: From first dose to 100 days after last dose (up to approximately 2.5 years) ]
  The number of participants experiencing serious adverse events (SAEs) to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. A SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or is an important medical event.
• The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation [ Time Frame: From first dose to 100 days after last dose (up to approximately 2.5 years) ]
  The number of participants experiencing adverse events (AEs) leading to discontinuation of study drug to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment.
• The Number of Participant Deaths [ Time Frame: From first dose to study completion (up to approximately 4 years 5 months) ]
  The number of deaths in each arm to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors.
• The Number of Participants With Clinical Laboratory Test Abnormalities (Hematology) [ Time Frame: From baseline to 100 days after last dose (up to approximately 2.5 years) ]
  The number of participants with clinical laboratory test abnormalities to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. Results will be categorized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life Threatening Grade 5 = Death Related to AE Baseline is defined as the last non-missing measurement prior to the first dosing date and time
• The Number of Participants With Clinical Laboratory Test Abnormalities (LIVER AND KIDNEY FUNCTION) [ Time Frame: From baseline to 100 days after last dose (up to approximately 2.5 years) ]
  The number of participants with clinical laboratory test abnormalities to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. Results will be categorized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life Threatening Grade 5 = Death Related to AE Baseline is defined as the last non-missing measurement prior to the first dosing date and time
• The Number of Participants With Clinical Laboratory Test Abnormalities (OTHER CHEMISTRY TESTING ) [ Time Frame: From baseline to 100 days after last dose (up to approximately 2.5 years) ]
  The number of participants with clinical laboratory test abnormalities to assess the overall safety and tolerability of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab in participants with advanced solid tumors. Results will be categorized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life Threatening Grade 5 = Death Related to AE Baseline is defined as the last non-missing measurement prior to the first dosing date and time

• Original Primary Outcome Measures (submitted: April 8, 2016): Incidence of AE's (adverse events) and SAE's (serious adverse events), AE's leading to discontinuation, deaths and clinical laboratory test abnormalities [ Time Frame: Approximately 4 years. ]

Current Secondary Outcome Measures (submitted: December 25, 2021)

• Objective Response Rate (ORR) [ Time Frame: From baseline up to approximately 2.5 years ]
  The total number of participants whose best overall response (BOR) is either a complete response (CR) or partial response (PR) based on assessment of tumor response using RECIST v1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions. Overall Response (OR) = CR + PR Baseline is defined as the last non-missing measurement prior to the first dosing date and time.
• Duration of Response (DOR) [ Time Frame: From baseline up to approximately 2.5 years ]
  The time between the date of first response and the subsequent date of disease progression or death (death after re-treatment will not be considered), whichever occurs first in participants with a best overall response (BOR) of complete response (CR) or partial response (PR). Best overall response (BOR) is assessed per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions. Baseline is defined as the last non-missing measurement prior to the first dosing date and time. Due to high percentage of censored response, median estimate may be misleading
• Progression Free Survival (PFS) Rate at 24 Weeks [ Time Frame: 24 weeks after first dose ]
  The percentage of treated participants remaining progression free and surviving at 24 weeks since the first dosing date.
• Cmax: Maximum Observed Serum Concentration [ Time Frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) ]
  The maximum observed serum concentration was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
• Tmax: Time of Maximum Observed Serum Concentration [ Time Frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) ]
  The time of maximum observed serum concentration was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab
• AUC(0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t [ Time Frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) ]
  The area under the serum concentration-time curve from time 0 to time t was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
• AUC(TAU): Area Under the Serum Concentration-time Curve in 1 Dosing Interval [ Time Frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) ]
  The area under the serum concentration-time curve in 1 dosing interval was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
• Ctau: Observed Serum Concentration at the End of a Dosing Interval When Intensive Samples Are Collected [ Time Frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) ]
  The observed serum concentration at the end of a dosing interval when intensive samples are collected was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
• CLT: Total Body Clearance [ Time Frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) ]
  The total body clearance was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
• Css-avg: Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) [ Time Frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) ]
  The average concentration over a dosing interval (AUC(TAU)/tau) was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
• AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Cmax) [ Time Frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) ]
  The ratio of an exposure measure at steady state to that after the first dose was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
• AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (AUC) [ Time Frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) ]
  The ratio of an exposure measure at steady state to that after the first dose was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
• AI: Accumulation Index. Ratio of an Exposure Measure at Steady State (Ctau) [ Time Frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) ]
  The ratio of an exposure measure at steady state to that after the first dose was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
• T-HALFeff: Effective Elimination Half-life That Explains the Degree of Accumulation Observed for a Specific Exposure Measure (Exposure Measure Includes AUC(TAU), Cmax) [ Time Frame: Cycle 1-9 timepoints can include (Pre-dose, 0.30, 4, 24, 72, 168, 336, 696 hours post dose) ]
  The effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab
• Ctrough: Trough Observed Plasma Concentration [ Time Frame: Cycle 1-17 timepoints can include (Pre-dose, 336, 504, 672 hours post dose) ]
  Trough observed plasma concentration (this includes predose concentrations and Ctau concentrations) was measured after dosing to assess the pharmacokinetics of BMS-986178 administered alone or in combination with Nivolumab and/or Ipilimumab. Note: The geometric CV was not calculated. Arithmetic % CV is reported instead.
• Frequency of Positive Anti-Drug Antibodies (ADA) to BMS-986178 [ Time Frame: Cycle 1-6 timepoints can include (Pre-dose, 696 hours post dose) ]
  The number of participants with positive anti-drug antibodies (ADA) is assessed to characterize the immunogenicity of BMS-986178 administered alone or in combination with nivolumab and/or ipilimumab. ADA Positive: A participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (>=) than baseline positive titer) at any time after initiation of treatment.
• Frequency of Positive Anti-Drug Antibodies (ADA) to Nivolumab [ Time Frame: Cycle 1-6 timepoints can include (Pre-dose, 336, 696 hours post dose) ]
  The number of participants with positive anti-drug antibodies (ADA) is assessed to characterize the immunogenicity of Nivolumab administered with BMS-986178 ADA Positive: A participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (>=) than baseline positive titer) at any time after initiation of treatment.
• Frequency of Positive Anti-Drug Antibodies (ADA) to Ipilimumab. [ Time Frame: Cycle 1-6 timepoints can include (Pre-dose, 696 hours post dose) ]
  The number of participants with positive anti-drug antibodies (ADA) is assessed to characterize the immunogenicity of Ipilimumab administered with BMS-986178 ADA Positive: A participant with at least one ADA-positive sample relative to baseline (ADA negative at baseline or ADA titer to be at least 4-fold or greater (>=) than baseline positive titer) at any time after initiation of treatment.
• The Number of Participants Showing a Change in Soluble OX40 and Peripheral OX40 Receptor Occupancy Pharmacodynamic Biomarkers in Part 8 [ Time Frame: Cycle 1-6 timepoints can include (Pre-dose, 24, 168, 336, 672, 1848 hours post dose) ]
  The Number of Participants Showing a Change in Soluble OX40 and Peripheral OX40 Receptor Occupancy Pharmacodynamic Biomarkers in Part 8. A threshold of 80% receptor occupancy following treatment was applied.
• Tumor Pharmacodynamics of BMS-986178 in Combination With Nivolumab or Nivolumab Monotherapy in Part 8 [ Time Frame: Screening, cycle 1-2 timepoints can include (Pre-dose, 336, 1848 hours post dose) ]
  Tumor pharmacodynamics of BMS-986178 in combination with nivolumab or nivolumab monotherapy
• The Number of Participants With Sustained T Cell Expansion With DPV-001 in Combination With Nivolumab or Nivolumab Monotherapy in Part 9 [ Time Frame: Cycle 1-6 timepoints can include (Pre-dose, 24, 168, 336, 672, 1848 hours post dose) ]
  The number of participants with Sustained T Cell Expansion with DPV-001 in Combination with Nivolumab or Nivolumab Monotherapy was assessed to show a change in pharmacodynamics biomarkers

Original Secondary Outcome Measures (submitted: April 8, 2016)

• Cmax (maximum observed serum concentration) for BMS-986178 alone and in combination with nivolumab or ipilimumab, if data permits [ Time Frame: Approximately 100 days after the final study drug administration (end of treatment) ]
• Tmax (time of maximum observed concentration) for BMS-986178 alone and in combination with nivolumab or ipilimumab, if data permits [ Time Frame: Approximately 100 days after the final study drug administration (end of treatment) ]
• AUC(0-t) (area under the concentration-time curve from time zero to the time) for BMS-986178 alone and in combination with nivolumab or ipilimumab, if data permits [ Time Frame: Approximately 100 days after the final study drug administration (end of treatment) ]
• AUC(TAU) (area under the concentration-time curve in 1 dosing interval) for BMS-986178 alone and in combination with nivolumab or ipilimumab, if data permits [ Time Frame: Approximately 100 days after the final study drug administration (end of treatment) ]
• Ctau (the observed concentration at the end of a dosing interval) for BMS-986178 alone and in combination with nivolumab or ipilimumab, if data permits [ Time Frame: Approximately 100 days after the final study drug administration (end of treatment) ]
• CLT (total body clearance) for BMS-986178 alone and in combination with nivolumab or ipilimumab, if data permits [ Time Frame: Approximately 100 days after the final study drug administration (end of treatment) ]
• Css-avg [average concentration over a dosing interval (AUC(TAU)/tau)] for BMS-986178 alone and in combination with nivolumab or ipilimumab, if data permits [ Time Frame: Approximately 100 days after the final study drug administration (end of treatment) ]
• AI [ratio of an exposure measure at steady state to that after the first dose (exposure measure includes AUC(TAU), Cmax and Ctau)] for BMS-986178 alone and in combination with nivolumab or ipilimumab, if data permits [ Time Frame: Approximately 100 days after the final study drug administration (end of treatment) ]
• T-HALFeff [effective elimination half-life to explain degree of accumulation for a specific exposure measure (exposure measure includes AUC(TAU), Cmax and Ctau)] for BMS-986178 alone and in combination with nivolumab or ipilimumab, if data permits [ Time Frame: Approximately 100 days after the final study drug administration (end of treatment) ]
• Ctrough [trough observed plasma concentrations (this includes pre-dose concentrations (C0) and Ctau)] for BMS-986178 alone and in combination with nivolumab or ipilimumab, if data permits [ Time Frame: Approximately 100 days after the final study drug administration (end of treatment) ]
• Immunoassay of anti-nivolumab antibody in combination with anti-BMS-986178 antibody [ Time Frame: Approximately 100 days after the final study drug administration (end of treatment) ]
• Immunoassay of anti-ipilimumab antibody in combination with anti-BMS-986178 antibody [ Time Frame: Approximately 100 days after the final study drug administration (end of treatment) ]
• Objective Response Rate (ORR) [ Time Frame: Approximately 2 years ]
• Progression Free Survival Rate (PFSR) [ Time Frame: Approximately 2 years ]
• Immunoassay of anti-BMS-986178 antibody alone [ Time Frame: Approximately 100 days after 6 months of treatment ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread
• Official Title: A Phase 1/2a Study of BMS-986178 Administered Alone or in Combination With Nivolumab and/or Ipilimumab in Subjects With Advanced Solid Tumors
• Brief Summary: The purpose of the study is to determine the safety and tumor-shrinking ability of experimental medication BMS-986178, when given by itself or in combination with Nivolumab and/or Ipilimumab, in participants with solid cancers that are advanced or have spread.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 1; Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Advanced Cancer

Intervention

• Drug: BMS-986178
  Specified dose on specified days
• Drug: Nivolumab
  Specified dose on specified days
  Other Names:

  • BMS-936558
  • Opdivo
• Drug: Ipilimumab
  Specified dose on specified days
  Other Names:

  • BMS-734016
  • Yervoy
• Biological: Tetanus vaccine
  Specified dose on specified days
• Biological: DPV-001 vaccine
  DPV-001 (UbiLT3 and UbiLT6): Specified dose on specified days
• Drug: Cyclophosphamide
  Specified dose on specified days

Study Arms

• Experimental: Part 1: Dose Escalation
  • BMS-986178 at specified doses at specified intervals
  • Enrollment is closed for this arm
  Intervention: Drug: BMS-986178
• Experimental: Part 2: Dose Escalation and Expansion
  • BMS-986178 in combination with Nivolumab at specified doses at specified intervals
  • Enrollment is closed for this arm
  Interventions:

  • Drug: BMS-986178
  • Drug: Nivolumab
• Experimental: Part 3: Dose Escalation and Expansion
  • BMS-986178 in combination with Ipilimumab at specified doses at specified intervals
  • Enrollment is closed for this arm
  Interventions:

  • Drug: BMS-986178
  • Drug: Ipilimumab
• Experimental: Part 4: Dose Schedule and Exploration
  • BMS-986178/Nivolumab at specified doses at specified intervals
  • Enrollment is closed for this arm
  Interventions:

  • Drug: BMS-986178
  • Drug: Nivolumab
• Experimental: Part 5: Dose Schedule and Exploration
  • BMS-986178/Ipilimumab at specified doses at specified intervals
  • Enrollment is closed for this arm
  Interventions:

  • Drug: BMS-986178
  • Drug: Ipilimumab
• Experimental: Part 6: Dose Safety and Expansion
  • BMS-986178/Ipilimumab/Nivolumab at specified doses at specified intervals
  • Enrollment is closed for this arm
  Interventions:

  • Drug: BMS-986178
  • Drug: Nivolumab
  • Drug: Ipilimumab
• Experimental: Part 7: Dose Safety and Expansion
  • BMS-986178/Ipilimumab/Nivolumab at specified doses at specified intervals
  • Enrollment is closed for this arm
  Interventions:

  • Drug: BMS-986178
  • Drug: Nivolumab
  • Drug: Ipilimumab
• Experimental: Part 8: Dose Exploration
  • BMS-986178/Nivolumab with tetanus vaccine at specified doses and interval
  • Enrollment is closed for this arm
  Interventions:

  • Drug: BMS-986178
  • Drug: Nivolumab
  • Biological: Tetanus vaccine
• Experimental: Part 9: Dose Exploration
  • BMS-986178/Nivolumab/DPV-001 vaccine/cyclophosphamide (cohort 1) at specified doses at specified intervals OR Nivolumab/DPV-001 vaccine/cyclophosphamide (cohort 2) at specified doses at specified intervals
  • Enrollment is open for this arm [Tumor type triple negative breast cancer (TNBC)]
  Interventions:

  • Drug: BMS-986178
  • Drug: Nivolumab
  • Biological: DPV-001 vaccine
  • Drug: Cyclophosphamide

• Publications *: Gutierrez M, Moreno V, Heinhuis KM, Olszanski AJ, Spreafico A, Ong M, Chu Q, Carvajal RD, Trigo J, Ochoa de Olza M, Provencio M, De Vos FY, De Braud F, Leong S, Lathers D, Wang R, Ravindran P, Feng Y, Aanur P, Melero I. OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 Jan 15;27(2):460-472. doi: 10.1158/1078-0432.CCR-20-1830. Epub 2020 Nov 4.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: December 25, 2021): 166
• Original Estimated Enrollment (submitted: April 8, 2016): 212
• Actual Study Completion Date: November 2, 2020
• Actual Primary Completion Date: November 2, 2020 (Final data collection date for primary outcome measure)

Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

For Part 9 (only arm open for enrollment):

• Stage IV metastatic or unresectable triple negative breast cancer (TNBC) with zero or one prior systemic therapies in the advanced metastatic setting
• Participants with < 12 months from receipt of last curative-intent chemotherapy are allowed; curative chemotherapy will be considered first-line therapy
• Prior receipt of chemotherapy in the (neo)adjuvant setting is acceptable, as long as completed greater than 6 months from start of treatment
• Tumor biopsy samples (mandatory pre- and on-treatment biopsies) are required for all participants enrolled
• Must have histologic or cytologic confirmation of a malignancy that is advanced (metastatic, recurrent, refractory, and/or unresectable) with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
• Men and women must agree to follow specific methods of contraception, if applicable

Exclusion Criteria:

• Must be immunotherapy treatment naïve, including no prior therapy with T cell immune checkpoint blocker (anti-PDL1, anti-PD1). Prior receipt of intralymphatic cytokine therapy (IRX-2) is acceptable (Part 9 only)
• Other active malignancy requiring concurrent intervention
• Prior therapy with any agent specifically targeting T-cell co-stimulation pathways such as anti-OX40 antibody, anti-CD137, anti- glucocorticoid-induced TNFR-related gene (anti-GITR) antibody, and anti-CD27
• Known or underlying medical or psychiatric condition and/or social reason that, in the opinion of the investigator or Sponsor, could make the administration of study drug hazardous to the participant or could adversely affect the ability of the participant to comply with or tolerate the study

Other protocol-defined inclusion/exclusion criteria apply

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Canada, Israel, Italy, Netherlands, Spain, United States
• Removed Location Countries: France

Administrative Information

• NCT Number: NCT02737475
• Other Study ID Numbers: CA012-004; 2015-004816-39 ( EudraCT Number )
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Bristol-Myers Squibb
• Original Responsible Party: Same as current
• Current Study Sponsor: Bristol-Myers Squibb
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Bristol-Myers Squibb; Bristol-Myers Squibb

• PRS Account: Bristol-Myers Squibb
• Verification Date: December 2021